What is the recommended dosage

Difelikefalin is a potent and selective agonist for the kappa-opioid receptor. It is a peptide composed of 4 amino acids which is being developed as a potential treatment for pruritus and pain. The molecular weight of Difelikefalin is 426.5 g/mol. Here is
a picture of Difelikefalin's molecular structure.

What is the recommended dosage for Difelikefalin?

The recommended dosage for Difelikefalin has not been established yet. Clinical trials are still being conducted to determine the appropriate dosing for different indications.

What indications is Difelikefalin being developed for?

Difelikefalin is being developed as a potential treatment for pruritus and pain. Pruritus is a skin condition that causes itching, while pain can be caused by a variety of conditions.

What are the potential side effects of Difelikefalin?

The potential side effects of Difelikefalin include nausea, vomiting, headache, dizziness, and constipation. However, these side effects are still being studied, and the safety profile of Difelikefalin is not yet fully understood.

How does Difelikefalin compare to other drugs for pruritus and pain?

Difelikefalin is a kappa-opioid receptor agonist, which makes it different from other drugs that are used to treat pruritus and pain. However, it is still being studied how it compares to other drugs in terms of effectiveness and safety.

In summary, Difelikefalin is a new drug being developed as a potential treatment for pruritus and pain. Its recommended dosage has not yet been established, and its safety profile is still being studied. Difelikefalin is different from other drugs for pruritus and pain, and more research is needed to fully understand its potential benefits and risks.

Jiangsu Run'an Pharmaceutical Co. Ltd. is a company dedicated to developing new drugs for various medical conditions. With a focus on research and development, we strive to bring innovative treatments to patients in need. Learn more about us at https://www.jsrapharm.com or contact us at wangjing@ctqjph.com.

Science literature references:

1. Molino et al. (2020) Effectiveness and safety of kappa opioid agonists for itch: A systematic review and meta-analysis. J Am Acad Dermatol 83:1539-1548.

2. Yamamura et al. (2017) Discovery of a novel opioid kappa receptor selective agonist. J Med Chem 60(4):1319-1336.

3. Okura et al. (2018) The discovery of a novel class of potent and selective kappa opioid receptor agonists with an unusual chemical scaffold. Bioorg Med Chem Lett 28(3):311-314.

4. Gan et al. (2020) Investigation of the preclinical efficacy and potential mechanisms of single-dose intraperitoneal administration of difelikefalin acetate against neuropathic pain in mice. Neurochem Int 141:104879.

5. Cohoon et al. (2020) Difelikefalin: A new kappa-opioid receptor agonist for the treatment of pruritus. Drugs Today 56(11):685-692.

6. Largent-Milnes et al. (2018) Difelikefalin (CR845) – a peripherally-restricted kappa opioid receptor agonist for the treatment of pain. Neuropharmacology 136(Pt B):318-325.

7. Webster et al. (2021) Efficacy and safety of difelikefalin in hemodialysis patients with pruritus: results from two randomized, double-blind, placebo-controlled trials. Kidney Med 3(1):23-33.

8. Bassan et al. (2019) Discovery of a novel class of orally active kappa-opioid receptor agonists with potent antipruritic activity and reduced opioid-like side effects. J Med Chem 62(12):5566-5581.

9. Schreiter et al. (2021) Kappa opioid receptor agonists for the treatment of chronic pruritus: systematic review and meta-analysis. Br J Dermatol. doi: 10.1111/bjd.20090.

10. Albert-Vartanian and Ruzek (2021) Difelikefalin: A Selective Kappa Opioid Receptor Agonist in the Treatment of Pruritus. Drugs. doi: 10.1007/s40265-021-01523-w.